Main conclusion
Of the calves with pyrexia caused by pneumonia, 25.7 per cent of those that were treated with an initial course of non-steroidal anti-inflammatory drug (NSAID) showed resolution of disease without the requirement for further treatment with antimicrobials, and no significant effect on the development of repeated pyrexia or daily liveweight gain. This suggests that a NSAID alone may be a useful first line treatment, provided adequate attention is given to ongoing monitoring to identify those cases that require additional antimicrobial treatment.
Approach
One hundred and fifty-four preweaning calves were fitted with continuous monitoring temperature probes (TempVerified FeverTag; Amarillo), programmed so a flashing LED light was triggered following six hours of a sustained ear canal temperature of at least 39.7°C. Once pyrexia was detected, calves were randomly allocated to treatment groups. Calves in Group 1 (NSAID) received 2 mg/kg flunixin meglumine (Allevinix; Merial) for three consecutive days, and Group 2 (antimicrobial) calves received 6 mg/kg gamithromycin (Zactran; Merial). If pyrexia persisted for 72 hours after the initial treatment, calves were given further treatment (Group 1 received the antimicrobial and Group 2 received the NSAID).
Results
A total of 83 calves (61.9 per cent) developed undifferentiated pyrexia, with a presumptive diagnosis of pneumonia through exclusion of other calf diseases. Group 1 calves (NSAID) were five times more likely (P=0.002) to require a second treatment (the antimicrobial) after 72 hours to resolve the pyrexia compared to the need to give Group 2 (antimicrobial) calves a second treatment (the NSAID). However, 25.7 per cent of calves in Group 1 did recover following NSAID treatment alone. The analysis of variance indicated there was no significant difference in the daily live weight gain of the calves between the treatment groups (P=0.632), with a mean daily liveweight gain of 0.64 kg/day (se 0.02). No calves died while participating in the study.
Interpretation
The results indicate that using NSAIDs as the first line treatment resulted the resolution of 25.7 per cent of pyrexias in calves; however, calves treated with a NSAID they were five times more likely (P=0.002) to require an additional treatment (antimicrobials) compared to those in which antibiotics were used as the first line of treatment. The initial treatment group had no significant effect on the daily liveweight gain or the prevalence of repeat pyrexia episodes experienced by the calves. A major limitation of this study was the lack of definitive diagnosis and pathogen identification from pyrexic calves, as this would have allowed more robust conclusions to be drawn regarding the nature of the primary respiratory disease pathogens.
Significance of findings
This study demonstrates the potential for reducing antimicrobial usage with NSAID initial treatment, as the delay in receiving the additional treatment of antimicrobials did not appear to have long-term detrimental effects on calf health up to six months of age. The use of NSAIDs may be an important strategy for clinicians providing treatment and safeguarding welfare while withholding antimicrobial treatments for possible viral aetiologies. There is a strong rationale for NSAID use in cases of pneumonia, primarily to reduce excessive inflammation Calf fitted with a monitoring temperature probe to alert when the ear canal temperature was at least 39.7ºC for six hours
